Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SEMGLEE safely and effectively. See full prescribing information for SEMGLEE. SEMGLEE® (insulin glargine-yfgn) injection, for subcutaneous use Initial U.S. Approval: 2021SEMGLEE® (insulin glargine-yfgn) is biosimilar* to LANTUS (insulin glargine).
Medication labelWhy this: Advisory · dailymed-prescription
SEMGLEE is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Limitations of Use SEMGLEE is not recommended for the treatment of diabetic ketoacidosis.
- generic_name
- insulin glargine-yfgn
- product_names
- insulin glargine-yfgn
- ndc
- 83257-012, 83257-011, 83257-012-31, 83257-012-32, 83257-012-33, 83257-011-11
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en